All Open Trials |
||||
Title |
Trial ID# |
Disease Indication |
Cell-Biologic Product |
PI |
Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 Attached to TCRz and 4-1BB Signaling Domains in Patients with Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated with Cell Therapy |
13BT022 |
Pediatric Leukemia/ |
Humanized CD19 redirected autologous T cells (huCART19) |
Shannon Maude, MD PhD |
A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia |
14BT022/ CCTL019B2205J |
Pediatric ALL |
Single dose of CTL019 transduced cells |
Stephan Grupp, |
Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Pediatric Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia |
15CT055 |
Pediatric ALL |
Autologous T cells expressing CD22 chimeric antigen |
Stephan Grupp, |
Pilot Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRζ and 4-1BB Signaling Domains in Patients with Chemotherapy Resistant of Refractory CD19+ Leukemia and Lymphoma. (PEDIATRIC version) |
CHP959 |
Pediatric ALL |
CD19 redirected autologous T cells (CART-19 T Cells) |
Stephan Grupp, MD PhD |
A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients, With or Without the CCR5 delta-32 Mutation, Pre-treated with Cyclophosphamide |
SB-728mR |
HIV |
ZFN Modified CD4+ T Cells |
Pablo Tebas, MD |
HER-2/neu pulsed DC1 vaccine combined with trastuzumab for patients with DCIS |
UPCC03114 |
DCIS |
DC Vaccine |
Brian Czerniecki, MD, PhD |
Dose Optimization Trial of Autologous T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (CART-19) in Patients With Relapsed or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL) |
UPCC03712 |
Leukemia |
CD19 redirected autologous T cells (CART-19-T Cells) |
Noelle Frey, MD |
Pilot Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Linked to TCRζ and 4-1BB Signaling Domains in Patients With Chemotherapy Relapsed or Refractory Hodgkin Lymphoma |
UPCC04414 |
Hodgkin Lymphoma |
CD19 RNA redirected autologous T cells (RNA CART19 cells) |
Jakub Svoboda, MD |
Randomized Phase II Trial of CD3/CD28 Activated Id-KLH Primed Autologous Lymphocytes in Patients With Myeloma Undergoing Autologous Transplant |
UPCC07409 |
Myeloma |
CD3/CD28 activated autologous lymphocytes |
Edward Stadtmauer, MD (UPenn) |
c-Met CAR in triple negative breast cancer |
UPCC13111 |
Breast Cancer |
C-MET CAR RNA redirected T cells |
Julia Tchou, MD PhD |
Phase IIA Study of Redirected Autologous T Cells Engineered to contain Anti-CD19 Attached to TCRz and 4-1BB Signaling Domains in Patients with Chemotherapy Resistant or Refractory CD19+ Lymphoma |
UPCC13413 |
Non-Hodgkin Lymphoma |
CD19 redirected autologous T cells (CART-19 or CTL019 cells) |
Stephen Schuster, MD |
Pilot Study Of Redirected Autologous T Cells Engineered To Contain an Anti-BCMA scFv Coupled To TCRζ And 4-1BB Signaling Domains in Patients With Relapsed and/or Refractory Multiple Myeloma (NCT02546167) |
UPCC14415 |
Multiple Myeloma |
CART-BCMA |
Adam D Cohen, MD |
Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL) |
UPCC18415 |
CLL/SLL |
CART19 + Ibrutinib |
Saar Gill, MD |
Pilot Study of Autologous T-cells Redirected to Mesothelin and CD19 with a Chimeric Antigen Receptor in Patients with Metastatic Pancreatic Cancer |
UPCC19214 |
Pancreatic Cancer |
Autologous CART-meso-19 T cells |
Andrew Ko, MD |
Phase II Study of redirected autologous T cells engineered to contain anti-CD19 attached to TCRz and 4-1BB signaling domains in patients with chemotherapy resistant or refractory acute lymphoblastic leukemia |
UPCC21413 |
Leukemia |
CD19 redirected autologous T cells (CART-19-T Cells) |
Noelle Frey, MD |
Pilot Phase I HER-2 Pulsed-DC Vaccine to Prevent Recurrence for Patients with HER-2 Driven High Risk Invasive Breast Cancer |
UPCC25113 |
Breast Cancer |
DC Vaccine |
Brian Czerniecki, MD PhD |
Pilot Phase 1 HER-2 Pulsed-DC Vaccine R-2 to Prevent Recurrence for Patients with HER-2 driven Invasive Breast Cancer Post Neo-adjuvant Therapy |
UPCC26113 |
Breast Cancer |
DC Vaccine |
Brian Czerniecki, MD PhD |
Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia |
UPCC31415 |
Acute Lymphoblastic Leukemia |
Autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) |
Noelle Frey, MD |
Pilot Study of Autologous T Cells Redirected to EGFRVIII - with A Chimeric Antigen Receptor in Patients with EGFRVIII+ Glioblastoma |
UPCC35313 |
Glioblastoma Multiform |
CART- EGFRvIII cells are autologous T cells transduced with a lentiviral vector to express anti- EGFRvIII scFv 41BB:TCRζ |
Donald M. O'Rourke, MD (UPenn) |
Open Cancer Trials |
||||
Title |
Trial ID# |
Disease Indication |
Cell-Biologic Product |
PI |
Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 Attached to TCRz and 4-1BB Signaling Domains in Patients with Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated with Cell Therapy |
13BT022 |
Pediatric Leukemia/ |
Humanized CD19 redirected autologous T cells (huCART19) |
Shannon Maude, MD PhD |
A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia |
14BT022/ CCTL019B2205J |
Pediatric ALL |
Single dose of CTL019 transduced cells |
Stephan Grupp, |
Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Pediatric Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia |
15CT055 |
Pediatric ALL |
Autologous T cells expressing CD22 chimeric antigen |
Stephan Grupp, |
Pilot Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRζ and 4-1BB Signaling Domains in Patients with Chemotherapy Resistant of Refractory CD19+ Leukemia and Lymphoma. (PEDIATRIC version) |
CHP959 |
Pediatric ALL |
CD19 redirected autologous T cells (CART-19 T Cells) |
Stephan Grupp, MD PhD |
HER-2/neu pulsed DC1 vaccine combined with trastuzumab for patients with DCIS |
UPCC03114 |
DCIS |
DC Vaccine |
Brian Czerniecki, MD, PhD |
Dose Optimization Trial of Autologous T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (CART-19) in Patients With Relapsed or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL) |
UPCC03712 |
Leukemia |
CD19 redirected autologous T cells (CART-19-T Cells) |
Noelle Frey, MD |
Pilot Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Linked to TCRζ and 4-1BB Signaling Domains in Patients With Chemotherapy Relapsed or Refractory Hodgkin Lymphoma |
UPCC04414 |
Hodgkin Lymphoma |
CD19 RNA redirected autologous T cells (RNA CART19 cells) |
Jakub Svoboda, MD |
Randomized Phase II Trial of CD3/CD28 Activated Id-KLH Primed Autologous Lymphocytes in Patients With Myeloma Undergoing Autologous Transplant |
UPCC07409 |
Myeloma |
CD3/CD28 activated autologous lymphocytes |
Edward Stadtmauer, MD (UPenn) |
c-Met CAR in triple negative breast cancer |
UPCC13111 |
Breast Cancer |
C-MET CAR RNA redirected T cells |
Julia Tchou, MD PhD |
Phase IIA Study of Redirected Autologous T Cells Engineered to contain Anti-CD19 Attached to TCRz and 4-1BB Signaling Domains in Patients with Chemotherapy Resistant or Refractory CD19+ Lymphoma |
UPCC13413 |
Non-Hodgkin Lymphoma |
CD19 redirected autologous T cells (CART-19 or CTL019 cells) |
Stephen Schuster, MD |
Pilot Study Of Redirected Autologous T Cells Engineered To Contain an Anti-BCMA scFv Coupled To TCRζ And 4-1BB Signaling Domains in Patients With Relapsed and/or Refractory Multiple Myeloma (NCT02546167) |
UPCC14415 |
Multiple Myeloma |
CART-BCMA |
Adam D Cohen, MD |
Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL) |
UPCC18415 |
CLL/SLL |
CART19 + Ibrutinib |
Saar Gill, MD |
Pilot Study of Autologous T-cells Redirected to Mesothelin and CD19 with a Chimeric Antigen Receptor in Patients with Metastatic Pancreatic Cancer |
UPCC19214 |
Pancreatic Cancer |
Autologous CART-meso-19 T cells |
Andrew Ko, MD |
Phase II Study of redirected autologous T cells engineered to contain anti-CD19 attached to TCRz and 4-1BB signaling domains in patients with chemotherapy resistant or refractory acute lymphoblastic leukemia |
UPCC21413 |
Leukemia |
CD19 redirected autologous T cells (CART-19-T Cells) |
Noelle Frey, MD |
Pilot Phase I HER-2 Pulsed-DC Vaccine to Prevent Recurrence for Patients with HER-2 Driven High Risk Invasive Breast Cancer |
UPCC25113 |
Breast Cancer |
DC Vaccine |
Brian Czerniecki, MD PhD |
Pilot Phase 1 HER-2 Pulsed-DC Vaccine R-2 to Prevent Recurrence for Patients with HER-2 driven Invasive Breast Cancer Post Neo-adjuvant Therapy |
UPCC26113 |
Breast Cancer |
DC Vaccine |
Brian Czerniecki, MD PhD |
Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia |
UPCC31415 |
Acute Lymphoblastic Leukemia |
Autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) |
Noelle Frey, MD |
Pilot Study of Autologous T Cells Redirected to EGFRVIII - with A Chimeric Antigen Receptor in Patients with EGFRVIII+ Glioblastoma |
UPCC35313 |
Glioblastoma Multiform |
CART- EGFRvIII cells are autologous T cells transduced with a lentiviral vector to express anti- EGFRvIII scFv 41BB:TCRζ |
Donald M. O'Rourke, MD (UPenn) |
Open HIV Trials |
||||
Title |
Trial ID# |
Disease Indication |
Cell-Biologic Product |
PI |
A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients, With or Without the CCR5 delta-32 Mutation, Pre-treated with Cyclophosphamide |
SB-728mR |
HIV |
ZFN Modified CD4+ T Cells |
Pablo Tebas, MD |